ACCESS Newswire

Sama CEO Wendy Gonzalez to Speak at CogX Leadership Summit on AI

Share

Gonzalez to discuss how to deploy responsible AI across an organization, and the importance of diverse leadership in fostering AI innovation and improving bottom line performance

LONDON, UNITED KINGDOM / ACCESSWIRE / October 3, 2024 / Sama, the leader in purpose-built, responsible enterprise AI with agile data labeling for model development and supervised fine-tuning, today announced that CEO Wendy Gonzalez will speak in two separate sessions at the upcoming CogX Leadership Summit on AI, taking place in London on October 7, 2024.

In her first session of the conference, slated for 12 noon in the Prince of Wales room, Gonzalez will join Gopal Ramchurn of Responsible AI UK and Nia Castelly, co-founder and head of legal at Checks, Google's AI-powered platform that helps developers build safer products by simplifying privacy compliance. Entitled Demystifying Responsible AI: A Guide for Leaders, this panel will explore the challenges, opportunities, regulatory considerations and strategies necessary to successfully deploy responsible AI.

Gonzalez will also participate in a panel discussion entitled AI Leadership: Unlocking Innovation through Diverse Voices, taking place at 2 pm in the Prince of Wales room. This session will include Sana Wajid, chief development officer at Fetch AI; Christian Tooley, senior manager, EMEA at Bain Capital; and Katie Lockwood, co-founding partner of Twin Path Ventures. The discussion, which will cover the critical need for diverse leadership in fostering AI-driven innovation, and its impact on market competitiveness and financial performance, will be moderated by Rula Awad, machine learning engineer at Women in AI.

"We are in such an exciting period of time, at the precipice of significant global changes thanks to the power and potential of AI. However, without a conscientious effort to ensure ethical and responsible AI practices that prioritize a diverse group of voices, we could be facing a future rife with problems," said Gonzalez. "CogX always brings together a wide range of experts who are at the forefront of creating the best possible future for AI. I'm thrilled to be a part of these important conversations to move the industry forward on the best path possible."

A certified B corp, Sama is committed to leading the industry in responsible AI, prioritizing compliance with critical AI legislation around the world. The company's impact mission has resulted in lifting over 68,000 individuals out of poverty, and its most recent Impact Report details significant strides toward its sustainability goals, including efforts to become net zero by 2050 and its role in the United Nations Global Compact (UNGC), the world's largest voluntary corporate sustainability initiative.

CogX Festival is a global event focused on the impact of artificial intelligence and emerging technology on industry, government and society. This year's conference will focus on the crucial question, "How to seize the AI opportunity?" Tickets are available with a 25% discount via https://www.cogxleadershipsummit.com/tickets.

About Sama

Sama is a global leader in data annotation solutions for computer vision, generative AI and large language models. Our solutions minimize the risk of model failure and lower the total cost of ownership through an enterprise ready ML-powered platform and SamaIQ™, actionable data insights uncovered by proprietary algorithms and a highly skilled on-staff team of over 5,000 data experts. 40% of FAANG companies and other major Fortune 50 enterprises, including GM, Ford and Microsoft, trust Sama to help deliver industry-leading ML models.

Driven by a mission to expand opportunities for underserved individuals through the digital economy, Sama is a certified B-Corp and has helped more than 68,000 people lift themselves out of poverty. An MIT-led Randomized Controlled Trial has validated its training and employment program. For more information, visit www.sama.com.

Sama Media Contact:
press@samasource.org

SOURCE: Sama



View the original press release on accesswire.com

Sama

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release

Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen

Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan

Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release

On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye